NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C. , Nov. 12, 2024 (GLOBE NEWSWIRE) — Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Related Posts
-
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
-
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
